Student Publications

  1. MH Elberry, NHE Darwish, SA Mousa (2017) Hepatitis C virus management: Potential impact of nanotechnology, Virol J, 14:88.
  2. P Gladfelter, NHE Darwish, SA Mousa (2017) Current status and future direction in the management of malignant melanoma, Melanoma Res, 27:403-410.
  3. JW Potts, SA Mousa (2017) Recent advances in management of autosomal-dominant polycystic kidney disease, Am J Health Syst Pharm, 74:1959-1968.
  4. ZT Sahli, J Jo, SA Mousa, FI Tarazi (2017) Clinical management of restless legs syndrome in end-stage renal disease patients, CNS Spectr, 22:14-21.
  5. LA Della Badia, NA Elshourbagy, SA Mousa (2016) Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol, Pharmacol Ther, 164:183-194.
  6. SM Brady, L Shapiro, SA Mousa (2016) Current and future direction in the management of scleroderma, Arch Derm Res, 308:461-471.
  7. BR Yasin, HA El-Fawal, SA Mousa (2015) Date (Phoenix dactylifera) polyphenolics and other bioactive compounds: A traditional islamic remedy’s potential in prevention of cell damage, cancer therapeutics and beyond, Int J Mol Sci, 16:30075-30090.
  8. F Tarazi, Z Sahil, J Pleskow, SA Mousa (2015) Asperger’s Syndrome: diagnosis, comorbidity and therapy. Expert Rev Neurother 15:281-293.
  9. V Belousova, AA Abd-Rabou, SA Mousa (2015) Recent Advances and Future Directions in the Management of Hepatitis C Infections. Pharmacol Ther 145C:92-102.
  10. R Vogel, EA Hussein, SA Mousa (2015) Stem Cells in the Management of Heart Failure: What Have We Learned from Clinical Trials? Expert Rev Cardiovasc Ther 13:75-83.
  11. DS Bombard, 2nd, SA Mousa (2014) Mayer-Rokitansky-Kuster-Hauser Syndrome: Complications, Diagnosis and Possible Treatment Options: A Review. Gynecol Endocrinol 30:618-623.
  12. J Ebright, SA Mousa (2014) Oral Anticoagulants and Status of Antidotes for the Reversal of Bleeding Risk. Clin Appl Thromb Hemost 21:105-114.
  13. FI Tarazi, ZT Sahli, M Wolny, SA Mousa (2014) Emerging Therapies for Parkinson’s Disease: From Bench to Bedside. Pharmacol Ther 144:123-133.


  1. T Sweezy, SA Mousa (2014) Genotype-Guided Use of Oral Antithrombotic Therapy: A Pharmacoeconomic Perspective. Personalized Medicine 11:223-235.
  2. M Thomas, SS Mousa, SA Mousa (2013) Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology 7:495-501.
  3. NE Larche, SA Mousa (2013) Riociguat for the Management of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Drugs of Today (Barc) 49:761-768.
  4. T Khushnud, SA Mousa (2013) Potential Role of Naturally Derived Polyphenols and Their Nanotechnology Delivery in Cancer. Molecular Biotechnology 55:78-86.
  5. AY Kardys, DJ Bharali, SA Mousa (2013) Amino-Functionalized Silica Nanoparticles: In Vitro Evaluation for Targeted Delivery and Therapy of Pancreatic Cancer. Journal of Nanotechnology DOI 10.1155/2013/768724.
  6. J Jalaly, J Dalfino, SA Mousa (2013) Onyx(R) in the Management of Cranial Arteriovenous Malformations. Expert Review of Medical Devices 10:453-459.
  7. SS Azad, ER Isenovic, S Yaturu, SA Mousa (2013) Insulin Therapy for Diabetes. In: Masuo K (ed) Type 2 Diabetes. InTech, DOI 10.5772/56379.
  8. CW Yang, SA Mousa (2012) The Effect of Red Yeast Rice (Monascus Purpureus) in Dyslipidemia and Other Disorders. Complementary Therapies in Medicine 20:466-474.
  9. D Swanson, R Block, SA Mousa (2012) Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Advances in Nutrition 3:1-7.
  10. J Stanekzai, ER Isenovic, SA Mousa (2012) Treatment Options for Diabetes: Potential Role of Stem Cells. Diabetes Research and Clinical Practice 98:361-368.
  11. NJ Rogers, SA Mousa (2012) The Shortcomings of Clinical Trials Assessing the Efficacy of Probiotics in Irritable Bowel Syndrome. Journal of Alternative and Complementary Medicine 18:112-119.
  12. H Patel, M Qari, SA Mousa (2012) Iron Balance in Β-Thalassemia: Maintaining an Antioxidant / Oxidant Ratio. Journal of Applied Hematology 3:4-11. Iron Balance in B-Thalassemia
  13. S Pabani, SA Mousa (2012) Current and Future Treatment of Pulmonary Hypertension. Drugs of Today 48:133-147.
  14. JC Keimer, SA Mousa (2012) Expanding the Role of Community Pharmacy: An Evaluation of Generic Drug Discount Programs, Pharmacy Based Immunization Services and Convenient Care Clinics. International Journal of Pharmacy 2:1-7.  Expanding the Role of Community Pharmacy
  15. G Beidoe, SA Mousa (2012) Current Primary Open-Angle Glaucoma Treatments and Future Directions. Clinical Ophthalmology 6:1699-1707.
  16. W Aman, S Mousa, G Shiha, SA Mousa (2012) Current Status and Future Directions in the Management of Chronic Hepatitis C. Virology Journal 9:57.
  17. J Ramli, P CalderonArtero, RC Block, SA Mousa (2011) Novel Therapeutic Targets for Preserving a Healthy Endothelium: Strategies for Reducing the Risk of Vascular and Cardiovascular Disease. Cardiology Journal 18:352-363.
  18. D Laurenzo, SA Mousa (2011) Mechanisms of Drug Resistance in Mycobacterium Tuberculosis and Current Status of Rapid Molecular Diagnostic Testing. Acta Tropica 119:5-10. Mechanisms of Drug Resistance in Mycobacterium Tuberculosis
  19. S Clayton, SA Mousa (2011) Therapeutics Formulated to Target Cancer Stem Cells: Is It in Our Future? Cancer Cell International 11:7.
  20. J-Y Byun, SA Mousa (2011) Thromboprophylaxis in Cancer Patients Receiving Bevacizumab. Journal of Applied Hematology 2:273-279. Thromboprophylaxis in Cancer Patients Receiving Bevacizumab

PRI Staff Publications

  1. AA Abd-Rabou, DJ Bharali, SA Mousa (2018) Taribavirin and 5-fluorouracil-loaded pegylated-lipid nanoparticle synthesis, p38 docking, and antiproliferative effects on MCF-7 breast cancer, Pharm Res, 35:76.
  2. PJ Davis, JL Leonard, HY Lin, M Leinung, SA Mousa (2018) Molecular basis of nongenomic actions of thyroid hormone, Vitam Horm, 106:67-96.
  3. A Hercbergs, SA Mousa, PJ Davis (2018) Nonthyroidal illness syndrome and thyroid hormone actions at integrin αvβ3, J Clin Endocrinol Metab, Feb. 1, 2018 [Epub ahead of print].
  4. A Hercbergs, SA Mousa, M Leinung, HY Lin, PJ Davis (2018) Thyroid hormone in the clinic and breast cancer, Horm Cancer, Feb. 13, 2018 [Epub ahead of print].
  5. AW Nana, YT Chin, CY Lin, Y Ho, JA Bennett, YJ Shih, YR Chen, CA Changou, JZ Pedersen, S Incerpi, LF Liu, J Whang-Peng, E Fu, WS Li, SA Mousa, HY Lin, PJ Davis (2018) Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer, Endocr Relat Cancer, 25:279-293.
  6. DJ Bharali, T Sudha, H Cui, BM Mian, SA Mousa (2017) Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer, Nanomedicine, 13:263-273.
  7. L Fu, K Li, D Mori, M Hirakane, L Lin, N Grover, P Datta, Y Yu, J Zhao, F Zhang, M Yalcin, SA Mousa, JS Dordick, RJ Linhardt (2017) Enzymatic generation of highly anticoagulant bovine intestinal heparin, J Med Chem, 60:8673-8679.
  8. MT Hsieh, LM Wang, CA Changou, YT Chin, YSH Yang, HY Lai, SY Lee, YN Yang, J Whang-Peng, LF Liu, HY Lin, SA Mousa, PJ Davis (2017) Crosstalk between integrin αvβ3 and ERα contributes to thyroid hormone-induced proliferation of ovarian cancer cells, Oncotarget, 8:24237-24249.
  9. JT Leith, PJ Davis, SA Mousa, AA Hercbergs (2017) In vitro effects of tetraiodothyroacetic acid combined with X-irradiation on basal cell carcinoma cells, Cell Cycle, 16:367-373.
    W Li, M Yalcin, Q Lin, MM Ardawi, SA Mousa (2017) Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery, J Control Release, 248:117-124.
  10. V Muralidharan-Chari, J Kim, SA Mousa (2017) Reversal of anticoagulant activity of heparin and low molecular weight heparins by poly-L-lysine: A comparative ‘in vitro’ study versus protamine sulfate, Thromb Res, 155:128-130.
  11. S Nallanthighal, C Chan, DJ Bharali, SA Mousa, E Vasquez, R Reliene (2017) Particle coatings but not silver ions mediate genotoxicity of ingested silver nanoparticles in a mouse model, NanoImpact, 5:92-100.
  12. M Rajabi, SA Mousa (2017) The role of angiogenesis in cancer treatment, Biomedicines, 5:34.
  13. M Srinivasan, DJ Bharali, T Sudha, M Khedr, I Guest, S Sell, GV Glinsky, SA Mousa (2017) Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation, Oncotarget, 8:38731-38742.
  14. T Sudha, DJ Bharali, S Sell, NHE Darwish, PJ Davis, SA Mousa (2017) Nanoparticulate tetrac inhibits growth and vascularity of glioblastoma xenografts, Horm Cancer, 8:157-165.
  15. T Sudha, DJ Bharali, M Yalcin, NH Darwish, MD Coskun, KA Keating, HY Lin, PJ Davis, SA Mousa (2017) Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac, Nanomed (Lond), 12:195-205.
  16. NHE Darwish, T Sudha, K Godugu, O Elbaz, HA Abdelghaffar, EEA Hassan, SA Mousa (2016) Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: Potential impact of BMI-1, TIM-3 and CLL-1, Oncotarget, 7:57811-57820.
  17. PJ Davis, GV Glinsky, HY Lin, SA Mousa (2016) Actions of thyroid hormone analogues on chemokines, J Immunol Res, 2016:3147671.
  18. A Hercbergs, PJ Davis, HY Lin, SA Mousa (2016) Possible contributions of thyroid hormone replacement to specific behaviors of cancer, Biomed Pharmacother, 84:655-659.
  19. HY Lin, YT Chin, AW Nana, YJ Shih, HY Lai, HY Tang, M Leinung, SA Mousa, PJ Davis (2016) Actions of L-thyroxine and nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells, Steroids, 114:59-67.
  20. V Muralidharan-Chari, J Kim, A Abuawad, M Naeem, HD Cui, SA Mousa (2016) Thymoquinone modulates blood coagulation in vitro via its effects on inflammatory and coagulation pathways, Int J Mol Sci, 17:474.
  21. V Muralidharan-Chari, HG Kohan, AG Asimakopoulos, T Sudha, S Sell, K Kannan, M Boroujerdi, PJ Davis, SA Mousa (2016) Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells, Oncotarget, 7:50365-50379.
  22. V Muralidharan-Chari, SA Mousa (2016) Heparin neutralizer anticoagulant reversal agent, Drugs of the Future, 41:341-346.
  23. M Rajabi, SA Mousa (2016) Lipid nanoparticles and their application in nanomedicine, Curr Pharm Biotech, 17:662-672.
  24. M Rajabi, T Sudha, NHE Darwish, PJ Davis, SA Mousa (2016) Synthesis of MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-angiogenesis modulator, Bioorg Med Chem Lett, 26:4112-4116.
  25. PJ Davis, T Sudha, HY Lin, SA Mousa (2015) Thyroid hormone, hormone analogs, and angiogenesis, Compr Physiol, 6:353-362.
  26. HY Lin, GV Glinsky, SA Mousa, PJ Davis (2015) Thyroid hormone and anti-apoptosis in tumor cells, Oncotarget, 6:14735-14743.
  27. M Rajabi, Z Hossaini, MA Khalilzadeh, S Datta, M Halder, SA Mousa (2015) Synthesis of a new class of furo [3,2-c] coumarins and its anticancer activity, J Photochem Photobiol B, 148:66-72.
  28. AMA Safer, NA Hanafy, DJ Bharali, HD Cui, SA Mousa (2015) Effect of green tea extract encapsulated into chitosan nanoparticles on hepatic fibrosis collagen fibers assessed by atomic force microscopy in rat hepatic fibrosis model, J Nanosci Nanotech, 15:6452-6459.
  29. W Hariri*, T Sudha*, DJ Bharali, H Cui, SA Mousa (2015) Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer. Pharm Res. 32:2764-2774. *Contributed equally
  30. A Bani-Jaber, H Cui, A Elsaid, M Yalcin, T Sudha, SA Mousa (2015) Pegylated Solid Lipid Nanoparticles Reconstituted From High-Density Lipoprotein components for Hepatic Targeting. ScienceJet 4:145.
  31. PJ Davis, GV Glinsky, HY Lin, JT Leith, A Hercbergs, HY Tang, O Ashur-Fabian, S Incerpi, SA Mousa (2015) Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac. Front Endocrinol 5:240.
  32. A Alshaiban, V Muralidharan-Chari, A Nepo, SA Mousa (2015) Modulation of Sickle Red Blood Cell Adhesion and Its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative. Clin Appl Thromb Hemost 22:230-238.
  33. R Alyahya, T Sudha, M Racz, SC Stain, SA Mousa (2015) Anti-Metastasis Efficacy and Safety of Non-Anticoagulant Heparin Derivative Versus Low Molecular Weight Heparin in Surgical Pancreatic Cancer Models. Int J Oncol 46:1225-1231.
  34. AB Shirode, DJ Bharali, S Nallanthighal, JK Coon, SA Mousa, R Reliene (2015) Nanoencapsulation of Pomegranate Bioactive Compounds for Breast Cancer Chemoprevention. Int J Nanomedicine 10:475-484.
  35. PJ Davis, HY Lin, T Sudha, M Yalcin, HY Tang, A Hercbergs, JT Leith, MK Luidens, O Ashur-Fabian, S Incerpi, SA Mousa (2014) Nanotetrac Targets Integrin Alphavbeta3 on Tumor Cells to Disorder Cell Defense Pathways and Block Angiogenesis. Onco Targets Ther 7:1619-1624. Nanotetrac Targets Integrin Alphavbeta3 on Tumor Cells
  36. IA Siddiqui, DJ Bharali, M Nihal, VM Adhami, N Khan, JC Chamcheu, MI Khan, S Shabana, SA Mousa, H Mukhtar (2014) Excellent Anti-Proliferative and Pro-Apoptotic Effects of (-)-Epigallocatechin-3-Gallate Encapsulated in Chitosan Nanoparticles on Human Melanoma Cell Growth Both in Vitro and in Vivo. Nanomedicine 10:1619-1626.
  37. T Sudha, M Yalcin, HY Lin, AM Elmetwally, T Nazeer, T Arumugam, P Phillips, SA Mousa (2014) Suppression of Pancreatic Cancer by Sulfated Non-Anticoagulant Low Molecular Weight Heparin. Cancer Letters 350:25-33.
  38. SA Mousa, HY Lin, HY Tang, A Hercbergs, MK Luidens, PJ Davis (2014) Modulation of Angiogenesis by Thyroid Hormone and Hormone Analogues: Implications for Cancer Management. Angiogenesis 17:463-469.
  39. N Khan, DJ Bharali, VM Adhami, IA Siddiqui, H Cui, SM Shabana, SA Mousa, H Mukhtar (2014) Oral Administration of Naturally Occurring Chitosan-Based Nanoformulated Green Tea Polyphenol Egcg Effectively Inhibits Prostate Cancer Cell Growth in a Xenograft Model. Carcinogenesis 35:415-423.

  1. M Yalcin, HY Lin, T Sudha, DJ Bharali, R Meng, HY Tang, FB Davis, SC Stain, PJ Davis, SA Mousa (2013) Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles. Hormones and Cancer 4:176-185.
  2. A Rebbaa, G Patil, M Yalcin, T Sudha, SA Mousa (2013) Ot-404, Multi-Targeted Anti-Cancer Agent Affecting Tumor Proliferation, Chemo-Resistance, and Angiogenesis. Cancer Letters 332:55-62.
  3. SA Mousa (2013) Comparative Pharmacodynamic Assessment of the Antiangiogenesis Activity of Heparin and Low-Molecular-Weight Heparin Fractions: Structure-Function Relationship. Clinical and Applied Thrombosis/Hemostasis 19:48-54.
  4. AA Lugade, DJ Bharali, V Pradhan, G Elkin, SA Mousa, Y Thanavala (2013) Single Low-Dose Un-Adjuvanted Hbsag Nanoparticle Vaccine Elicits Robust, Durable Immunity. Nanomedicine 9:923-934.
  5. HY Lin, YF Su, MT Hsieh, S Lin, R Meng, D London, C Lin, HY Tang, J Hwang, FB Davis, SA Mousa, PJ Davis (2013) Nuclear Monomeric Integrin Alphav in Cancer Cells Is a Coactivator Regulated by Thyroid Hormone. FASEB Journal 27:3209-3216.
  6. PJ Davis, SA Mousa, V Cody, HY Tang, HY Lin (2013) Small Molecule Hormone or Hormone-Like Ligands of Integrin Alphavbeta3: Implications for Cancer Cell Behavior. Hormes and Cancer 4:335-342.
  7. PJ Davis, HY Lin, HY Tang, FB Davis, SA Mousa (2013) Adjunctive Input to the Nuclear Thyroid Hormone Receptor from the Cell Surface Receptor for the Hormone. Thyroid 23:1503-1509.
  8. PJ Davis, GV Glinsky, HY Lin, S Incerpi, FB Davis, SA Mousa, HY Tang, A Hercbergs, MK Luidens (2013) Molecular Mechanisms of Actions of Formulations of the Thyroid Hormone Analogue, Tetrac, on the Inflammatory Response. Endocrine Research 38:112-118.
  9. DJ Bharali, M Yalcin, PJ Davis, SA Mousa (2013) Tetraiodothyroacetic Acid-Conjugated Plga Nanoparticles: A Nanomedicine Approach to Treat Drug-Resistant Breast Cancer. Nanomedicine (London) 8:1943-1954.
  10. DJ Bharali, SA Mousa (2013) Relevance of Nanotechnology in Modulating Oxidative Stress: An Overview. Methods in Molecular Biology 1028:289-292.
  11. DJ Bharali, D Armstrong, SA Mousa (2013) Hybrid Polymeric Nanoparticles: Potential Candidate for Ophthalmic Delivery. Methods in Molecular Biology 1028:279-286.
  12. T Sudha, P Phillips, C Kanaan, RJ Linhardt, L Borsig, SA Mousa (2012) Inhibitory Effect of Non-Anticoagulant Heparin (S-Nach) on Pancreatic Cancer Cell Adhesion and Metastasis in Human Umbilical Cord Vessel Segment and in Mouse Model. Clin Exp Metastasis 29:431-439.
  13. MH Qari, U Dier, SA Mousa (2012) Biomarkers of Inflammation, Growth Factor, and Coagulation Activation in Patients with Sickle Cell Disease. Clinical and Applied Thrombosis/Hemostasis 18:195-200.
  14. SA Mousa, M Yalcin, DJ Bharali, R Meng, HY Tang, HY Lin, FB Davis, PJ Davis (2012) Tetraiodothyroacetic Acid and Its Nanoformulation Inhibit Thyroid Hormone Stimulation of Non-Small Cell Lung Cancer Cells in Vitro and Its Growth in Xenografts. Lung Cancer 76:39-45.
  15. SA Mousa (2012) The Future of Anticoagulant Therapy. Cardiovascular Therapeutics 30:255-256.
  16. HY Lin, HY Tang, FB Davis, SA Mousa, S Incerpi, MK Luidens, R Meng, PJ Davis (2012) Nongenomic Regulation by Thyroid Hormone of Plasma Membrane Ion and Small Molecule Pumps. Discovery Medicine 14:199-206. Nongenomic Regulation by Thyroid Hormone
  17. MS Jayaraman, DJ Bharali, T Sudha, SA Mousa (2012) Nano Chitosan Peptide as a Potential Therapeutic Carrier for Retinal Delivery to Treat Age-Related Macular Degeneration. Molecular Vision 18:2300-2308.
  18. A Aljada, SA Mousa (2012) Metformin and Neoplasia: Implications and Indications. Pharmacology & Therapeutics 133:108-115.